SGLT2 inhibitors serve as a foundational therapy for cardiovascular outcomes in patients with heart failure with preserved and mildly reduced ejection fraction regardless of diabetes.
Meta-Analysis
Do SGLT2 inhibitors reduce cardiovascular death and/or urgent visits/hospitalization for heart failure in patients with heart failure with preserved or mildly reduced ejection fraction regardless of baseline diabetes?
This meta-analysis supports SGLT2 inhibitors as a foundational therapy for patients with heart failure with preserved or mildly reduced ejection fraction, regardless of diabetes status.
AIM: To provide a pooled effect of sodium-glucose cotransporter-2 inhibitors (SGLT2i) on cardiovascular outcomes in patients with heart failure with preserved ejection fraction (HFpEF: ≥50%) or/and mildly reduced EF (HFmrEF: 41-49%) regardless of baseline diabetes. METHODS: We systemically searched PubMed/MEDLINE, Embase, Web of Science databases and clinical trial registries using appropriate keywords till August 28, 2022, to identify randomized controlled trials (RCTs) or post-hoc analysis of RCTs, reporting cardiovascular death (CVD) and/or urgent visits/hospitalization for heart failure(HHF) in patients with HFmrEF/HFpEF receiving SGLTi vs. placebo. Hazard ratios (HR) with 95% confidence intervals (CI) for outcomes were pooled together using generic inverse variance method with fixed-effects model. RESULTS: = 0%). CONCLUSIONS: This meta-analysis established the place of SGLT2i as a foundational therapy among patients with HF with preserved and mildly reduced EF regardless of diabetes.
Banerjee et al. (Wed,) conducted a meta-analysis in Heart failure with mildly reduced and preserved ejection fraction. Sodium-glucose cotransporter-2 inhibitors (SGLT2i) vs. Placebo was evaluated on Cardiovascular death and/or urgent visits/hospitalization for heart failure. SGLT2 inhibitors serve as a foundational therapy for cardiovascular outcomes in patients with heart failure with preserved and mildly reduced ejection fraction regardless of diabetes.